RA
AGIO icon

Royce & Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Royce & Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,338
Closed -$215K – 870
2024
Q1 		$215K Buy
+7,338
New +$196K ﹤0.01% 831

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royce & Associates's AGIO Position: Q2 2024 in Review

Royce & Associates sold out of Agios Pharmaceuticals (AGIO) in Q2 2024, closing a stake of 7,338 shares — an estimated $215K sold.

Royce & Associates first reported a position in AGIO in Q1 2024 and held it in 1 quarter. The position peaked at $215K in Q1 2024. 206 funds tracked by Wall St. Rank hold AGIO as of Q2 2024.

  • Royce & Associates reported no remaining Agios Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Royce & Associates sold 7,338 Agios Pharmaceuticals shares in Q2 2024, an estimated $215K.
  • Royce & Associates first reported a position in Agios Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Royce & Associates's Agios Pharmaceuticals position peaked at $215K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2024.

Based on Royce & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.